AC
ACOG.KL
—
Bursa Malaysia
Pharmaceuticals
Acog.Kl
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
1,25 %
Op margin
—
ROE
3,9 %
Net margin
2,8 %
Debt / equity
0,11
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$5,88
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
ACOG.KL operates in the electrical components and equipment industry, primarily generating revenue through the distribution and sale of industrial goods.
Business. Alpha Cognition Inc (ACOG.O) is a pharmaceutical company operating within the Healthcare sector, specifically focused on pharmaceuticals and medical research. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. As segment and geographic breakdowns are not disclosed, the company is described at the industry level as an entity engaged in pharmaceutical product sales.
Classification99 %
SectorHealth Care
Industry groupPharmaceuticals
Generated · model-assisted
Sell-side consensus
BUY2 analysts
2 buy0 hold0 sell
Avg 12m price target16,00
Analyst recommendations
2 analysts · consensus BuyBuy2
Hold0
Sell0
12-month price target
16,00
Consensus of sell-side coverage.
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
2 analysts · indicative
Ownership→
Raymond James & Associates, Inc.
largest disclosed fund holder
Profitability→
3,9 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to ACOG.KL. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
Alpha Cognition Inc (ACOG.O) is a pharmaceutical company operating within the Healthcare sector, specifically focused on pharmaceuticals and medical research. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. As segment and geographic breakdowns are not disclosed, the company is described at the industry level as an entity engaged in pharmaceutical product sales.
Classification99 %
SectorHealth Care
Industry groupPharmaceuticals
AI synthesis
GENERATEDACOG.KL maintains a relatively conservative capital structure, with a debt-to-equity ratio of 0.11, indicating a low reliance on debt financing. The company's liquidity position is assessed as medium, with operating cash flow of MYR 9.11 million in the latest period, which is partially offset by capital expenditures of MYR 1.27 million. Despite a net cash position that is negative after subtracting total debt, the company's equity base of MYR 101.09 million provides a buffer against short-term liquidity pressures.
Profitability metrics show a return on equity of 3.94%, which is below the industry median for electrical components and equipment firms. This suggests that ACOG.KL is underperforming in terms of generating returns for shareholders relative to its peers. The company's net income of MYR 3.98 million on revenue of MYR 140.99 million indicates a net margin of approximately 2.83%, which is also below the industry average.
The company's revenue is concentrated in the industrial goods segment, with no disclosed geographic diversification in the latest financial data. This lack of geographic segmentation suggests that ACOG.KL may be more vulnerable to regional economic fluctuations or supply chain disruptions. There is no indication of multiple business lines or product categories, which could limit the company's ability to adapt to changing market conditions.
Looking ahead, ACOG.KL's growth trajectory appears modest, with no significant revenue growth or contraction reported in the latest period. The company's capital expenditures are relatively low, suggesting a conservative approach to reinvestment and expansion. While this may help preserve liquidity, it could also limit long-term growth potential if market opportunities arise that require increased investment.
The risk assessment highlights a medium liquidity risk, primarily due to the company's negative net cash position after accounting for total debt. Although dilution risk is currently low, the company's capital structure and financing decisions will need to be closely monitored in the coming periods. No recent events or filings have been disclosed that would significantly alter the company's risk profile or strategic direction.
Key takeaways
- ACOG.KL has a low debt-to-equity ratio, indicating a conservative capital structure.
- The company's return on equity is below the industry median, suggesting suboptimal shareholder returns.
- Revenue is concentrated in a single segment, increasing exposure to sector-specific risks.
- Capital expenditures are minimal, which may limit long-term growth potential.
- Liquidity risk is moderate, with a negative net cash position after debt.
Bull / Bear case
Generated · model-assisted— missing data
In focus — financials by report
Valuation
Market price
$0,16
Market cap
—
Enterprise valueⓘ
—
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
—
P / Tangible bookⓘ
—
Tangible book
—
Net cashⓘ
-$11.4M
Current ratioⓘ
—
Debt / equityⓘ
0.1
ROAⓘ
—
ROEⓘ
3.9%
Cash conversionⓘ
229.0%
CapEx / revenueⓘ
-0.9%
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Business relationships
— missing data
Supply chain
— missing data
Peer comparison
Peer comparison8 peers · vs ACOG · multiples and returns
JN
JNJ—
Johnson & Johnson
$254,43
622,1B USDP/E
23,5x
— vs self
Div yield
2,0 %
— vs self
ROE
33,0 %
+2 810,8 vs self
LL
LLY—
ELI LILLY AND COMPANY
$1 124,04
1,01T USDP/E
52,0x
— vs self
Div yield
0,5 %
— vs self
ROE
66,2 %
+2 843,9 vs self
MR
MRK—
MERCK & CO., INC.
—
—P/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
PF
PFE—
Pfizer Inc
$25,05
143,6B USDP/E
18,2x
— vs self
Div yield
6,9 %
— vs self
ROE
8,6 %
+2 786,4 vs self
AB
ABBV—
Abbvie Inc
$245,10
434,8B USDP/E
110,6x
— vs self
Div yield
2,5 %
— vs self
ROE
-63,5 %
+2 714,2 vs self
AZ
AZN—
AZN.L
$157,59
—P/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
BM
BMY—
Bristol-myers Squibb Co
$65,60
134,3B USDP/E
17,7x
— vs self
Div yield
4,1 %
— vs self
ROE
31,6 %
+2 809,3 vs self
GS
GSK—
Gsk Plc-spon Adr
—
—P/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
Market position
Stress test
— missing data
Predictor forecast
Next quarternear-term
Earnings · next quarterconf 45 %
EPS
Consensus EPS
-1,37
Predicted surprise
+0,00
Beat probability
45 %
Analysts
2
Other metrics
Revenue
—
no estimate
Segment revenue
—
no estimate
Margin
—
no estimate
Segment margin
—
no estimate
as of 2026-05-16 · Earnings Surprise V1
Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
Probabilistic model output — not investment advice. · generated 2026-08-04
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$14,00
Mean$16,00
Median$16,00
High$18,00
Spot$0,16
+9900.0 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskMedium
Filing-based flags
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Net Margin2,8 %Below median
ROE3,9 %Above median
Capex / Rev-0,9 %Above P75
D/E0,11Above median
Cash Conv2,29Above P75
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net acquired 49 176 sh6 grants6 insiders
- Director · Common Share Options → Common SharesAcquired 6 991 @ $6,65grant · 2026-04-16
- Director · Common Share Options → Common SharesAcquired 8 437 @ $6,56grant · 2026-01-14
- Director · Common Share Options → Common SharesAcquired 8 437 @ $6,56grant · 2026-01-14
- Director · Common Share Options → Common SharesAcquired 8 437 @ $6,56grant · 2026-01-14
- Director · Common Share Options → Common SharesAcquired 8 437 @ $6,56grant · 2026-01-14
- Director · Common Share Options → Common SharesAcquired 8 437 @ $6,56grant · 2026-01-14
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
How metrics are computed
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
Source documents
- ACOG.KL Market data — financials · 2026-05-27
Ownership & reference
Top holders
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
Insider activity
Net buying40 buys · 0 sellsnet $3,2M8 insiders · last 365d
- 10% owner · Common Stock, no par valueBought 4 550 @ $5,99$27K · 2026-06-15
- 10% owner · Common Stock, no par valueBought 273 @ $5,93$2K · 2026-06-12
- 10% owner · Common Stock, no par valueBought 2 862 @ $5,91$17K · 2026-06-11
- 10% owner · Common Stock, no par valueBought 5 872 @ $5,99$35K · 2026-06-10
- 10% owner · Common Stock, no par valueBought 24 856 @ $5,98$149K · 2026-06-09
- 10% owner · Common Stock, no par valueBought 10 054 @ $5,83$59K · 2026-06-05
- 10% owner · Common Stock, no par valueBought 70 577 @ $5,90$416K · 2026-05-29
- 10% owner · Common Stock, no par valueBought 2 000 @ $5,83$12K · 2026-05-28
- 10% owner · Common Stock, no par valueBought 1 161 @ $5,73$7K · 2026-05-27
- 10% owner · Common Stock, no par valueBought 15 945 @ $5,70$91K · 2026-05-21
- 10% owner · Common Stock, no par valueBought 8 431 @ $5,89$50K · 2026-05-20
- Chief Operating Officer · Common SharesBought 3 500 @ $5,76$20K · 2026-05-19
- 10% owner · Common Stock, no par valueBought 17 395 @ $5,69$99K · 2026-05-18
- 10% owner · Common Stock, no par valueBought 16 648 @ $5,83$97K · 2026-05-15
- Director · Common SharesOther 5 489 · 2026-04-16
- 10% owner · Common Stock, no par valueBought 1 850 @ $4,99$9K · 2026-03-30
- 10% owner · Common Stock, no par valueBought 10 000 @ $5,08$51K · 2026-03-27
- 10% owner · Common Stock, no par valueBought 7 319 @ $5,28$39K · 2026-03-26
- 10% owner · Common Stock, no par valueBought 8 581 @ $5,43$47K · 2026-03-25
- 10% owner · Common Stock, no par valueBought 4 182 @ $5,59$23K · 2026-03-24
- 10% owner · Common Stock, no par valueBought 2 094 @ $5,71$12K · 2026-03-19
- 10% owner · Common Stock, no par valueBought 2 481 @ $5,75$14K · 2026-03-18
- 10% owner · Common Stock, no par valueBought 1 331 @ $5,78$8K · 2026-03-16
- 10% owner · Common Stock, no par valueBought 7 358 @ $5,75$42K · 2026-03-13
- 10% owner · Common Stock, no par valueBought 5 708 @ $5,85$33K · 2026-03-12
Short positioning
215.6Kshares short+66.0% vs prior
3.52days to cover
8.9%short of daily vol
371fails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
ACOG.KLCanonical
Bursa Malaysia · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskMedium
Net cash is negative after subtracting total debt.
Evidence & claims
From filings & derived data- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 59.9%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 57.1%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 47.7%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -162.8%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): -88.6%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): -39.8%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 42.2%Derived (calculated)
- Return on equity (FY 2025-12-31): -33.1%Derived (calculated)
- Net margin (FY 2025-12-31): -202.2%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): -52.4%Derived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): 999.2%Derived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.28xDerived (calculated)
- Current ratio (FY 2025-12-31): 8.65xDerived (calculated)
- Return on assets (FY 2025-12-31): -25.9%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 42.6%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 36.0%Derived (calculated)
- Total operating expenses (annual): USD 32.88MSEC XBRL filing
- Net income (annual): USD -20.67MSEC XBRL filing
- EPS (basic) (annual): USD-PER-SHARES -1SEC XBRL filing
- Shares outstanding (annual): 21.74MSEC XBRL filing
- Current assets (annual): USD 79.01MSEC XBRL filing
- Operating cash flow (annual): USD -20.38MSEC XBRL filing
- Current liabilities (annual): USD 9.13MSEC XBRL filing
- Shareholders' equity (annual): USD 62.53MSEC XBRL filing
Showing 24 of 60 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
2026-06-15 00:00 UTCINSIDER6 insider transactions — 2026-06 · net buy $288k
2026-06-15INSIDEROpaleye Management Inc. bought 4.5k sh Common Stock, no par value — 10% owner ~$27k
2026-06-12INSIDEROpaleye Management Inc. bought 273 sh Common Stock, no par value — 10% owner ~$2k
2026-06-11INSIDEROpaleye Management Inc. bought 2.9k sh Common Stock, no par value — 10% owner ~$17k
2026-06-10INSIDEROpaleye Management Inc. bought 5.9k sh Common Stock, no par value — 10% owner ~$35k
2026-06-09INSIDEROpaleye Management Inc. bought 24.9k sh Common Stock, no par value — 10% owner ~$149k
2026-06-05INSIDEROpaleye Management Inc. bought 10.1k sh Common Stock, no par value — 10% owner ~$59k
2026-05-29 00:00 UTCINSIDER8 insider transactions — 2026-05 · net buy $791k
2026-05-29INSIDEROpaleye Management Inc. bought 70.6k sh Common Stock, no par value — 10% owner ~$416k
2026-05-28INSIDEROpaleye Management Inc. bought 2.0k sh Common Stock, no par value — 10% owner ~$12k
2026-05-27INSIDEROpaleye Management Inc. bought 1.2k sh Common Stock, no par value — 10% owner ~$7k
2026-05-21INSIDEROpaleye Management Inc. bought 15.9k sh Common Stock, no par value — 10% owner ~$91k
2026-05-20INSIDEROpaleye Management Inc. bought 8.4k sh Common Stock, no par value — 10% owner ~$50k
2026-05-19INSIDERD'Angelo Lauren bought 3.5k sh Common Shares — Chief Operating Officer ~$20k
2026-05-18INSIDEROpaleye Management Inc. bought 17.4k sh Common Stock, no par value — 10% owner ~$99k
2026-05-15INSIDEROpaleye Management Inc. bought 16.6k sh Common Stock, no par value — 10% owner ~$97k
2026-04-16 00:00 UTCINSIDER2 insider transactions — 2026-04 1 derivative
2026-04-16INSIDERSensenig Bethany transacted 5.5k sh Common Shares — Director
2026-04-16INSIDERSensenig Bethany acquired 7.0k sh Common Share Options — Director
2026-03-30 00:00 UTCINSIDER18 insider transactions — 2026-03 · net buy $1.1M
2026-03-30INSIDEROpaleye Management Inc. bought 1.9k sh Common Stock, no par value — 10% owner ~$9k
2026-03-27INSIDEROpaleye Management Inc. bought 10.0k sh Common Stock, no par value — 10% owner ~$51k
2026-03-26INSIDEROpaleye Management Inc. bought 7.3k sh Common Stock, no par value — 10% owner ~$39k
2026-03-25INSIDEROpaleye Management Inc. bought 8.6k sh Common Stock, no par value — 10% owner ~$47k
2026-03-24INSIDEROpaleye Management Inc. bought 4.2k sh Common Stock, no par value — 10% owner ~$23k
2026-03-19INSIDEROpaleye Management Inc. bought 2.1k sh Common Stock, no par value — 10% owner ~$12k
2026-03-18INSIDEROpaleye Management Inc. bought 2.5k sh Common Stock, no par value — 10% owner ~$14k
2026-03-16INSIDEROpaleye Management Inc. bought 1.3k sh Common Stock, no par value — 10% owner ~$8k
2026-03-13INSIDEROpaleye Management Inc. bought 7.4k sh Common Stock, no par value — 10% owner ~$42k
2026-03-12INSIDEROpaleye Management Inc. bought 5.7k sh Common Stock, no par value — 10% owner ~$33k
2026-02-27 00:00 UTCINSIDER8 insider transactions — 2026-02 · net buy $1.0M
Showing the 40 most recent of 51 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data
Premium coverage